LUNG PULMONX CORP revenue, earnings and financials

For the quarter ended June 30, 2026, PULMONX CORP reported revenue of $22.8M (down 4.6% from a year earlier), net income of −$10.1M and diluted EPS of −$0.24; over the last four quarters revenue was $87.4M and net income −$48.1M; for the fiscal year ended December 2025 revenue was $90.5M, up 8.0% on the year before.

LUNG annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $90.5M, gross profit $67.1M, operating income −$53.7M, net income −$54.0M (margin -59.7%), EPS −$1.33
• Fiscal year ended Dec 2024: revenue $83.8M, gross profit $62.0M, operating income −$57.7M, net income −$56.4M (margin -67.3%), EPS −$1.44
• Fiscal year ended Dec 2023: revenue $68.7M, gross profit $50.8M, operating income −$61.9M, net income −$60.8M (margin -88.6%), EPS −$1.60
• Fiscal year ended Dec 2022: revenue $53.7M, gross profit $39.9M, operating income −$58.6M, net income −$58.9M (margin -109.8%), EPS −$1.59
• Fiscal year ended Dec 2021: revenue $48.4M, gross profit $35.6M, operating income −$47.3M, net income −$48.7M (margin -100.5%), EPS −$1.35

LUNG quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $22.8M (down 4.6% year over year), net income −$10.1M, EPS −$0.24
• Quarter ended Mar 31, 2026: revenue $20.6M (down 8.7% year over year), net income −$13.7M, EPS −$0.33
• Quarter ended Dec 31, 2025 (from the annual report): revenue $22.6M (down 4.9% year over year), net income −$10.4M, EPS −$0.25
• Quarter ended Sep 30, 2025: revenue $21.5M (up 5.5% year over year), net income −$14.0M, EPS −$0.34
• Quarter ended Jun 30, 2025: revenue $23.9M (up 14.8% year over year), net income −$15.2M, EPS −$0.38
• Quarter ended Mar 31, 2025: revenue $22.5M (up 19.5% year over year), net income −$14.4M, EPS −$0.36
• Quarter ended Dec 31, 2024 (from the annual report): revenue $23.8M (up 23.3% year over year), net income −$13.2M, EPS −$0.33
• Quarter ended Sep 30, 2024: revenue $20.4M (up 15.4% year over year), net income −$14.1M, EPS −$0.36
• Quarter ended Jun 30, 2024: revenue $20.8M (up 20.9% year over year), net income −$15.3M, EPS −$0.39
• Quarter ended Mar 31, 2024: revenue $18.9M (up 29.7% year over year), net income −$13.7M, EPS −$0.36
• Quarter ended Dec 31, 2023 (from the annual report): revenue $19.3M (up 25.0% year over year), net income −$13.9M, EPS −$0.36
• Quarter ended Sep 30, 2023: revenue $17.7M (up 30.9% year over year), net income −$14.9M, EPS −$0.39
• Quarter ended Jun 30, 2023: revenue $17.2M (up 23.3% year over year), net income −$16.2M, EPS −$0.43
• Quarter ended Mar 31, 2023: revenue $14.5M (up 34.8% year over year), net income −$15.9M, EPS −$0.42
• Quarter ended Dec 31, 2022 (from the annual report): revenue $15.4M (up 12.5% year over year), net income −$14.3M, EPS −$0.38
• Quarter ended Sep 30, 2022: revenue $13.5M (up 1.8% year over year), net income −$14.2M, EPS −$0.38
• Quarter ended Jun 30, 2022: revenue $14.0M (up 14.3% year over year), net income −$14.6M, EPS −$0.40
• Quarter ended Mar 31, 2022: revenue $10.8M (up 16.7% year over year), net income −$15.8M, EPS −$0.43
• Quarter ended Dec 31, 2021 (from the annual report): revenue $13.7M, net income −$13.0M, EPS −$0.36
• Quarter ended Sep 30, 2021: revenue $13.3M, net income −$10.2M, EPS −$0.28

LUNG cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$32.4M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$31.5M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$37.6M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$45.1M, share buybacks $27.0K
• Fiscal year ended Dec 2021: operating cash flow −$41.4M, share buybacks $26.0K

LUNG balance sheet

• Jun 30, 2026: cash $55.8M, total assets $115M, total liabilities $75.5M, shareholders' equity $39.2M, long-term debt $37.4M
• Mar 31, 2026: cash $61.6M, total assets $120M, total liabilities $74.2M, shareholders' equity $45.8M, long-term debt $37.2M
• Dec 31, 2025: cash $69.8M, total assets $129M, total liabilities $75.2M, shareholders' equity $54.1M, long-term debt $37.0M
• Sep 30, 2025: cash $76.5M, total assets $138M, total liabilities $78.2M, shareholders' equity $60.0M, long-term debt $37.0M
• Jun 30, 2025: cash $75.5M, total assets $147M, total liabilities $78.1M, shareholders' equity $69.1M, long-term debt $37.0M
• Mar 31, 2025: cash $74.6M, total assets $151M, total liabilities $73.1M, shareholders' equity $77.7M, long-term debt $29.4M
• Dec 31, 2024: cash $70.9M, total assets $163M, total liabilities $77.0M, shareholders' equity $85.8M, long-term debt $34.0M
• Sep 30, 2024: cash $63.3M, total assets $167M, total liabilities $73.5M, shareholders' equity $93.9M, long-term debt $37.1M

What is LUNG's revenue?

PULMONX CORP reported $87.4M of revenue over its last four quarters, through June 30, 2026.

Is LUNG profitable?

No. PULMONX CORP lost $48.1M over the last four quarters.

What is LUNG's EPS?

Diluted earnings per share over the last four quarters were −$1.16; −$0.24 in the latest quarter.

LUNG ownership and insider trades · All stocks